NCT00482079View on ClinicalTrials.gov

A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

PHASE2CompletedINTERVENTIONAL
Enrollment

743

Participants

Timeline

Start Date

May 13, 2003

Primary Completion Date

August 25, 2004

Study Completion Date

June 15, 2006

Conditions
Diabetes Mellitus, Type II
Interventions
DRUG

MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks

DRUG

Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00482079 - A Study of MK0431 in Patients With Type 2 Diabetes (0431-010) | Biotech Hunter | Biotech Hunter